Results 31 to 40 of about 57,996 (259)
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]
, 2019 Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core +1 more source
Systematic identification of non-coding pharmacogenomic landscape in cancer
Nature Communications, 2018 In this study the authors build lncRNA-drug response models for 265 anti-cancer agents across 27 cancer types. They report their cancer cell line based lncRNA EN-models are able to effectively predict therapeutic outcome for breast cancer, ovarian cancer,
Yue Wang +6 more
doaj +1 more source
Pharmacogenomic testing and its future in community pharmacy [PDF]
, 2020 Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core +1 more source
The Oncologist, EarlyView., 2021 Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi +21 more
wiley +1 more source
Integrating rare genetic variants into pharmacogenetic drug response predictions
Human Genomics, 2018 Background Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions.
Magnus Ingelman-Sundberg +3 more
doaj +1 more source
miRNAs as Key Players in the Management of Cutaneous Melanoma
Cells, 2020 The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso +4 more
doaj +1 more source
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]
, 2015 Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM +10 more
core +3 more sources
British Journal of Cancer, 2004 The large number of active combination chemotherapy regimens for most cancers has led to the need for better information to guide the 'standard' treatment for each patient. In an attempt to individualise therapy, pharmacogenetics and pharmacogenomics (a polygenic approach to pharmacogenetic studies) encompass the search for answers to the hereditary ...
Marsh, S, McLeod, H L
openaire +3 more sources
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]
, 2014 Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V +3 more
core +2 more sources
Introduction : biofutures/biopresents [PDF]
, 2006 Two very different reports produced for the UK government in the last three years have connected the state of our physical health with that of our material wealth. The first of these was produced in 2003 by the Bioscience Innovation and Growth Team (BIGT)
Birch, Kean
core +1 more source